28,655 Shares in Novo Nordisk A/S $NVO Purchased by Coppell Advisory Solutions LLC

Key Points

• Coppell Advisory Solutions LLC bought a new stake of 28,655 shares in Novo Nordisk during Q2, valued at about $1.96 million.
• Analyst sentiment is mixed but consensus is a Hold with an average price target of $53.33, while firms like Sanford C. Bernstein and Rothschild Redb upgraded coverage and Morgan Stanley and Jefferies remain more negative.
• Novo Nordisk beat quarterly EPS estimates ($1.02 vs. $0.77) but revenue was slightly below expectations; the stock trades near $50 (market cap ~$223.8B) and is down markedly year‑to‑date from a 1‑year high of $109.88.

Coppell Advisory Solutions LLC purchased a new stake in Novo Nordisk A/S (NYSE:NVO - Free Report) during the second quarter, according to its most recent disclosure with the SEC. The firm purchased 28,655 shares of the company's stock, valued at approximately $1,963,000.

Several other large investors also recently bought and sold shares of NVO. NewSquare Capital LLC lifted its position in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company's stock valued at $31,000 after acquiring an additional 282 shares in the last quarter. Disciplina Capital Management LLC raised its stake in Novo Nordisk A/S by 162.3% in the 1st quarter. Disciplina Capital Management LLC now owns 480 shares of the company's stock valued at $33,000 after purchasing an additional 297 shares during the last quarter. Mid American Wealth Advisory Group Inc. purchased a new position in Novo Nordisk A/S in the 2nd quarter valued at $37,000. State of Wyoming acquired a new stake in Novo Nordisk A/S during the 1st quarter worth $38,000. Finally, Maseco LLP acquired a new stake in Novo Nordisk A/S during the 2nd quarter worth $39,000. 11.54% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NVO. Sanford C. Bernstein raised shares of Novo Nordisk A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, September 9th. Rothschild Redb raised shares of Novo Nordisk A/S from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, September 16th. Dbs Bank upgraded Novo Nordisk A/S from a "strong sell" rating to a "hold" rating in a research report on Friday, August 22nd. Morgan Stanley reaffirmed an "underweight" rating and issued a $42.00 price target on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Finally, Jefferies Financial Group started coverage on Novo Nordisk A/S in a research note on Monday, October 27th. They set an "underperform" rating on the stock. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and three have assigned a Sell rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $53.33.

Novo Nordisk A/S Stock Down 0.3%

Shares of NYSE NVO opened at $50.12 on Friday. The company has a market capitalization of $223.79 billion, a P/E ratio of 14.57 and a beta of 0.67. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.57. The company has a 50 day simple moving average of $50.86 and a 200-day simple moving average of $58.36. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $109.88.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. The company had revenue of $11.79 billion during the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. On average, equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.